Area of research
Oncology · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include Medicine, Cabozantinib, Cancer research, Biology, Tumor microenvironment, and Prostate cancer.
Heterotypic cell–cell communication regulates glandular stem cell multipotency
Identification of the tumour transition states occurring during EMT
Early lineage segregation of multipotent embryonic mammary gland progenitors
Cabozantinib Affects Osteosarcoma Growth Through A Direct Effect On Tumor Cells and Modifications In Bone Microenvironment
Classification of M1/M2-polarized human macrophages by label-free hyperspectral reflectance confocal microscopy and multivariate analysis
Statins and the Brain: More than Lipid Lowering Agents?
Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions
Nanofibers of Human Tropoelastin-inspired peptides: Structural characterization and biological properties
AMPK in the central nervous system: physiological roles and pathological implications
M1-polarized macrophages as predictor of poor response to trabectedin treatment in myxoid liposarcoma.
New Molecular Targets in Metastatic Prostate Cancer
Integrin a5 is an independent prognosis factor and a potential therapeutic target for breast cancer bone metastasis
Biological effects of cabozantinib on bone microenvironment.
Biological effects of Cabozantinib on bone microenvironment
Biological effects of cabozantinib on osteosarcoma-bone microenvironment model
Biological effects of Cabozantinib on bone microenvironment
Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment
Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence
Deregulation of dicer and mir-155 expression in liposarcoma
Emerging drugs for the treatment of bone metastasis
Long non-coding RNA HSAT II as a new biomarker for the identification of high risk intraductal papillary mucinous neoplasms (IPMNs)
Long non-coding RNA HSAT II as a new biomarker for the identification of high risk intraductal papillary mucinous neoplasms (IPMNs).
MicroRNAs and Bone Metastasis: A New Challenge
Targeting Bone Metastases: New Drugs for New Targets